Lower Newborn Bone Mineral Content Associated with Maternal Use of Tenofovir Disoproxil Fumarate during Pregnancy

Clinical Infectious Diseases

Volumn 61, Issue 6, 2015, Pages 996-1003

  Siberry, George K ^a   Jacobson, Denise L ^b   Kalkwarf, Heidi J ^c   Wu, Julia W ^d   Dimeglio, Linda A ^e   Yogev, Ram ^f   Knapp, Katherine M ^g   Wheeler, Justin J ^h   Butler, Laurie ⁱ   Hazra, Rohan ^a   Miller, Tracie L ^j   Seage, George R ^d   Van Dyke, Russell B ^k   Barr, Emily ^l   Davtyan, Mariam ^m   Mofenson, Lynne M ^a   Rich, Kenneth C ⁿ  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e INDIANA UNIVERSITY HEALTH   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h TUFTS UNIVERSITY   (United States)

ⁱ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF COLORADO   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

HIV; infant bone mineral content; intrauterine exposure; tenofovir

Indexed keywords

TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ADULT; ARTICLE; BONE MINERAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GESTATIONAL AGE; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEWBORN; OUTCOME ASSESSMENT; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY; VIRUS LOAD; BONE DENSITY; CROSS-SECTIONAL STUDY; HIV INFECTIONS; MATERNAL EXPOSURE; PREGNANCY COMPLICATIONS, INFECTIOUS; UNITED STATES;

ADULT; ANTI-HIV AGENTS; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TENOFOVIR; UNITED STATES;

EID: 84940639472     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ437     Document Type: Article

References (43)

1. World Health Organization consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2013. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/. Accessed 15 March 2015.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 15 March 2015.
3. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
4. Stellbrink H-J, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-72.
5. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. J Infect Dis 2011; 203:1791-801.
6. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152:582-4.
7. Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
8. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIVnegative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011; 6:e23688.
9. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIVinfected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-504.
10. Young B, Dao CN, Buchacz K, Baker R, Brooks JT; HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-8.
11. Griner R, Williams PL, Read JS, et al; Pediatric HIV/AIDS Cohort Study. In utero and postnatal exposure to antiretrovirals among HIVexposed but uninfected children in the United States. AIDS Patient Care STDs 2011; 25:385-94.
12. Panel on Treatment ofHIV-Infected PregnantWomen and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed 15 March 2015.
13. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29:207-20.
14. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48:1469-87.
15. Van Rompay KKA, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesusmacaques frominfancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144-60.
16. Siberry GK,Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151-9.
17. Ransom CE, Huo Y, Patel K, et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr 2013; 64:374-81.
18. Gibb DM, Kizito H, Russell EC, et al; DART Trial Team. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9:e1001217.
19. Viganò A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011; 16:1259-66.
20. Jacobson DL, Patel K, Siberry GK, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study (PHACS). Am J Clin Nutr 2011; 94:1485-95.
21. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000; 314:1-27.
22. Fenton TR, Sauve RS. Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart. Eur J Clin Nutr 2007; 61:1380-5.
23. Gallo S, Vanstone CA, Weiler HA. Normative data for bone mass in healthy term infants from birth to 1 year of age. J Osteoporos 2012; 2012:672403.
24. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, BulterysM. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis 2013; 57:1773-81.
25. Picaud JC, Decullier E, Plan O, et al. Growth and bone mineralization in preterm infants fed preterm formula or standard term formula after discharge. J Pediatr 2008; 153:616-21.
26. Kalkwarf HJ, Zemel BS, Yolton K, Heubi JE. Bone mineral content and density of the lumbar spine of infants and toddlers: influence of age, sex, race, growth, and human milk feeding. J Bone Miner Res 2013; 28:206-12.
27. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008; 93:861-8.
28. Clark EM, Ness AR, Bishop NJ, Tobias JH. Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 2006; 21:1489-95.
29. Clark EM, Tobias JH, Ness AR. Association between bone density and fractures in children: a systematic review and meta-analysis. Pediatrics 2006; 117:e291-7.
30. Hernandez CJ, Beaupre GS, Carter DR. A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis. Osteoporos Int 2003; 14:843e7.
31. Gale CR, Martyn CN, Kellingray S, Eastell R, Cooper C. Intrauterine programming of adult body composition. J Clin Endocrinol Metab 2001; 86:267-72.
32. Winsloe C, Earl S, Dennison EM, Cooper C, Harvey NC. Early life factors in the pathogenesis of osteoporosis. Curr Osteoporos Rep 2009; 7:140-4.
33. Puthanakit T, Saksawad R, Bunupuradah T, et al. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 61:477-83.
34. Dimeglio LA, Wang J, Siberry GK, et al. Bone mineral density in children and adolescents with HIV infection. AIDS 2013; 27:21120.
35. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-61.
36. Hill A, Khoo S, Back D, Pozniak A, Boffito M. Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors? J Int AIDS Soc 2014; 17(4 suppl 3):19583.
37. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56:412-9.
38. Havens PL, Stephensen CB, Hazra R, et al. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 54:1013-25.
39. Overton ET, Chan ES, Brown TT, et al; ACTG A5280 Study Team. 21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston, MA, Abstract 133.
40. Natarajan CK, Sankar MJ, Agarwal R, et al. Trial of daily vitamin D supplementation in preterm infants. Pediatrics 2014; 133:e628-34.
41. Gallo S, Comeau K, Vanstone C, et al. Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial. JAMA 2013; 309:1785-92.
42. Moyer-Mileur LJ, Ball SD, Brunstetter VL, Chan GM. Maternal-administered physical activity enhances bone mineral acquisition in premature very low birth weight infants. J Perinatol 2008; 28:432-7.
43. Study of effects of tenofovir on bone health and kidneys during pregnancy and breastfeeding. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01066858?term=siberry&rank=4. Accessed 15 March 2015.